首页> 外文期刊>British Journal of Pharmaceutical Research >Clinical Efficacy of Topical Terbinafine Versus Topical Luliconazole in Treatment of Tinea Corporis/Tinea Cruris Patients
【24h】

Clinical Efficacy of Topical Terbinafine Versus Topical Luliconazole in Treatment of Tinea Corporis/Tinea Cruris Patients

机译:外用圣经经文卢利康唑特比萘芬治疗体癣/蛾类患者的临床疗效

获取原文
           

摘要

Aims: Tinea corporis & cruris of skin respond well to topical antifungal therapy, but there is a need to apply cream 2- 3 times daily for up to four weeks will impair compliance & lead to treatment failure. Luliconazole is one of those drugs offering good efficacy & tolerability with a short duration of treatment. Terbinafine, an allylamine antifungal agent, acts by selective inhibition of fungal squalene epoxidase. Luliconazole, an imidazole antifungal agent is considered to be more effective in inhibition of ergosterol biosynthesis and its reservoir property in stratum corneum is greater than that of terbinafine. As there are lack of studies between terbinafine & luliconazole, the present study was undertaken to compare the clinical efficacy in tinea corporis/tinea cruris patients. Study Design: Prospective parallel study. Place and Duration of Study: Study was conducted on 60 patients presenting to the Dermatology out-patient department of RL Jalapa Hospital, Kolar, from 1st December 30th April 2012. Methodology: Patients alternatively assigned to either terbinafine or luliconazole & advised to apply test drugs topically for 14 days. Clinical symptoms & signs were assessed using 4-point (pruritus, erythema, scaling) scale & 10% KOH mount at base line, end of treatment visit (15th day) & later 30th day. The data was analysed based on age, gender distribution, duration of lesion, clinical score & KOH mount. Results: Of the 60 patients recruited, all came for 1st follow up (14th day) & 51 patients for 2nd follow-up (30th day). Mean age of the patients was 33.80± 9.58 years in terbinafine & 33.90 ± 9.58 years luliconazole group. Majority of patients were in 12- 40 years aged in both group. Sixty patients and 51 patients were negative for KOH mount preparation on 15th & 30th day respectively. At the end of first follow-up, the clinical score was reduced from 3 to zero (P=0.0001) in both the treatment groups. Mycological cure was 100% in both the drug groups. There was no relapse in 51 patients who came for 2nd follow-up. Four in terbinafine and 5 in luliconazole group were lost to follow up. Conclusion: Only mild forms of tinea infections were included as compared to other studies where moderate to severe (pustules, incrustations, vesiculation). Hence the onset of illness, treatment duration and severity of illness were favorable in this study for two weeks. In both the treatment arms, clinical & mycological cure was comparable, hence once a day application for two weeks of terbinafine & luliconazole were equally effective for treatment of tinea corporis/cruris infection.
机译:目的:体癣和皮肤皱纹对局部抗真菌治疗反应良好,但有必要每天使用乳膏2至3次,持续4周,这会损害依从性并导致治疗失败。卢立康唑是在短期治疗中具有良好疗效和耐受性的药物之一。特比萘芬(烯丙胺抗真菌剂)通过选择性抑制真菌角鲨烯环氧酶起作用。咪唑类抗真菌药卢立康唑被认为在抑制麦角固醇的生物合成方面更有效,其在角质层中的储藏特性大于特比萘芬。由于特比萘芬和卢立康唑之间缺乏研究,因此本研究旨在比较股癣/股癣患者的临床疗效。研究设计:前瞻性平行研究。研究的地点和持续时间:自2012年4月1日至12月30日,对60名就诊于Kolar RL Jalapa医院皮肤科门诊的患者进行了研究。方法:选择特比萘芬或卢立康唑的患者,建议局部应用试验药物治疗14天。使用4点(瘙痒,红斑,结垢)量表和基线时,就诊结束(第15天)和第30天之后的10%KOH坐位评估临床症状和体征天。根据年龄,性别分布,病变持续时间,临床评分和KOH坐骨分析数据。结果:在入选的60例患者中,所有患者均进行了1 s 随访(14 sup 天),51例患者进行了2 随访(第30个 天)。特比萘芬组的平均年龄为33.80±9.58岁,卢立康唑组的平均年龄为33.90±9.58岁。两组中大多数患者年龄在12至40岁之间。分别在第15天和第30天的KOH支架准备阴性60例和51例。在第一次随访结束时,两个治疗组的临床评分均从3降低至零(P = 0.0001)。两组药物的真菌学治愈率均为100%。随访2 的51例患者没有复发。特比萘芬组4例,卢立康唑组5例失访。结论:与其他中度至重度(脓疱,结rust,囊泡)研究相比,仅包括轻度癣感染。因此,在本研究中,为期两周的疾病发作,治疗持续时间和疾病严重程度均令人满意。在两个治疗方面,临床和真菌学治疗方法均具有可比性,因此每天两次应用特比萘芬和卢立康唑的治疗对体癣//疮的感染同样有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号